ENVB – Enveric Bioscience – Helping Cancer Patients Recover-Top Cannabinoid Stock-Rated Bullish May1
David Johnson, CEO of Enveric Biosciences, a patient-first biotechnology company developing rigorously tested, novel cannabinoid medicines to improve quality of life for cancer patients. It’s been a while since the Green Rush team has talked about CBD so we used this opportunity to get an update on the state of the space including how CBD is fitting into the existing medical landscape, the ways that technology is progressing the validation of these molecules and what the market could look like in the next several years. We also explore Enveric’s business model and how they compare to other players in the industry as well as key news from the industry including Jazz Pharmaceuticals acquisition of GW Pharma. CEO David Johnson has 35 years of leading small, medium and Large companies in the Medical Device Space, both Public and Private. He has developed vast experience in all Global Markets, managing global businesses for over 20 years and living and working in three different countries. He has completed raising funds in both a private equity marketplace and in public markets for Micro cap companies. He has experience in a variety of sectors in the device space: Distribution of Medical Supplies; Wound Care; Orthopedics; Diabetes and Hospital Based Single Use Disposable Products in the OR and ICU. Arash Asher, M.D., Director of Cancer Rehabilitation and Survivorship at the Cedars-Sinai Cancer Center, to the Company’s Scientific Advisory Board. “We believe that Dr. Asher’s decision to join Enveric’s Scientific Advisory Board gives the Company a significant advantage given his extensive time and expertise at Cedars-Sinai,” said David Johnson, Chairman and CEO, Enveric Biosciences. “Our mission at Enveric is focused on improving cancer patients’ quality of life through leveraging the power of cannabinoid medicines. Dr. Asher’s deep knowledge of chemotherapy-induced peripheral neuropathy and more should help us achieve this goal of bringing safe, effective care to cancer patients who continue to suffer from their treatment side effects.” Dr. Douglas D. Lind to its board of directors. Dr. Lind has more than 30 years of experience working in a variety of life science-related professions, ranging from a former practicing physician, to a senior Wall Street equity research analyst at Morgan Stanley. Dr. Lind currently serves as a co-founder and Managing Partner at Biomark Capital, a Greenwich, Connecticut-based healthcare venture firm, where his investment focus includes cellular therapy, medical imaging, peripheral vascular disease and oncology. “Enveric is a patient-focused company targeting support care indications for cancer treatment side effects, a goal that we are keen on achieving, which requires the right team,” said Dave Johnson, CEO of Enveric Biosciences. “With Dr. Lind’s extensive and diverse background working in both healthcare and finance, we are confident that he will add tremendous value in helping Enveric bring better treatment options to cancer patients in need.” Dr. Lind is a graduate of the University of Iowa College of Medicine. He was a practicing physician in Brookline, Massachusetts and was an attending physician at St. Elizabeth’s Hospital in Boston, a major teaching affiliate of Tufts University School of Medicine. While there, Dr. Lind completed his residency training in Internal Medicine.
Enjoy the Free Video – Add to Watch List DISCLAIMER: Futures, stocks and options trading involves substantial risk of loss and is not suitable for every investor. The valuation of futures, stocks and options may fluctuate, and, as a result, clients may lose more than their original investment. The impact of seasonal and geopolitical events is already factored into market prices. DO NOT BASE ANY INVESTMENT DECISION UPON ANY INFORMATION FOUND ON THIS WEBSITE. PLEASE BE ADVISED THAT YOUR CONTINUED USE OF THIS SITE OR THE INFORMATION PROVIDED HEREIN SHALL INDICATE YOUR CONSENT AND AGREEMENT TO THESE TERMS